Pharmicell Co., Ltd. (KRX:005690)

Market Cap	984.07B
Revenue (ttm)	23.94B
Net Income (ttm)	-26.78B
Shares Out	60.00M
EPS (ttm)	-613.75
PE Ratio	n/a
Forward PE	n/a
Dividend	20.00 (0.12%)
Ex-Dividend Date	Dec 27, 2024

Volume	4,560,552
Average Volume	4,500,159
Open	17,370
Previous Close	18,530
Day's Range	16,450 - 17,780
52-Week Range	4,420 - 20,800
Beta	0.46
RSI	48.76
Earnings Date	n/a

About Pharmicell

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company’s products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1968
• Country: South Korea
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 005690

Financial Performance

In 2013, Pharmicell's revenue was 33.41 billion, an increase of 200.63% compared to the previous year's 11.11 billion. Losses were -25.70 billion, 45.7% more than in 2012.